Down go the dominoes. The out-of-the-loop financial media will probably blame this largely on the Fed ending its MBS program but let’s be honest about the real factor behind it: remedial economics. Surprise surprise; when the market is flooded with supply with few takers, you get bond auctions like we got last week.
For more than a year, analysts have been warning that record sized debt sales by the US Treasury were at odds with a 10-year yield sitting comfortably below 4 per cent. This week, the yield on 10-year notes jumped from 3.65 per cent to a peak of 3.92 per cent on Thursday. On Friday it was 3.87 per cent.
I’m afraid someone has to point out the obvious here: credit markets don’t like getting the crack unceremoniously taken away, no more than the investors who have been buying into this ridiculousness thinking the free money will never end. Guess what? It’s over.
Mortgage investors got an unwelcome wake-up call last week after Treasury yields surged, a jolt that indicated that the Federal Reserve’s exit from the market may not go as smoothly as thought.
As the yield on 10-year Treasury notes jumped, yields on Fannie Mae’s benchmark 30-year bond followed, rising to 4.45% from 4.33%. That sent mortgage rates above 5%.
It was an unsettling surge as the Fed prepares to end its $1.25 trillion program of buying mortgage securities on Wednesday. Many in the market had come to believe the Fed’s exit would have little effect on mortgage bonds. They reasoned there were enough investors hungry for extra yield that they would step in to buy once the Fed left.
Here’s what I see… the skittish Fed, scared to death to let markets work out their own kinks lest they allow the cancerous bits to rot off (that might put Fannie and Freddie in an uncomfortable position), backpedals on its plan to start unloading MBSs and instead holds on to (and/or increases) its holdings to wait out the expiration of the first-time homebuyer credit in April, despite dismal numbers after the December extension. If you call 180,000 new…
At the end of August, we did a follow up article on what we believe is a far bigger marginal driver to the price of oil than OPEC production (which may or may not be reduced by up to 750kbpd in November), namely the Strategic Petroleum Reserve of China, a major importer of oil in recent years, along with India, taking advantage of low prices and largely supporting global oil demand growth at a time of rampant oversupply, and which we profiled most recently in "A ...
Looks or money? Brains or beauty? Value or growth?
The world is full of false dichotomies.
In the stock market, investors seek companies with good earnings growth (the growth school) and/or companies with bargain stock prices (the value school).
It is sometimes possible to find both in one stock. Right now I think D.R. Horton Inc., Skechers USA Inc., Taro Pharmaceutical Industries Ltd., Douglas Dynamics Inc. and United Therapeutics Inc. qualify.
Below looks at Commodities ETF DBC over the past decade. Since the highs in 2008, DBC has been a great asset to avoid. Is it time to start paying attention and potentially own this hard hit ETF? Check out the rare price situation below in DBC.
CLICK ON CHART TO ENLARGE
The CRB (Commodities Index) has been down 5-years in a row, this has never happened in the history of commoditi...
In early 2009, the seven largest publicly traded college operators were worth a combined $51 billion. Today, they’ve been all but wiped out.
When Barack Obama took office, America’s seven largest publicly traded college operators were worth a combined $51 billion, with more than 815,000 students enrolled at campuses spread across the country. The schools were flooded with with people seeking shelter from the recession, returning to school to pick up new skills.
Almost eight years later, the industry has been decimated. The seven largest listed operators are worth just over $6 billion, and the most valuable co...
Reminder: OpTrader is available to chat with Members, comments are found below each post.
This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).
We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options.
Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.
To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here
I was so pleased yesterday by the announcement that I have joined the Research team at GoldCore as it meant that I could finally start talking about it and was back in a role that lets me indulge in my passion by researching and geeking out on all things gold, silver and money.
Reminder: Pharmboy is available to chat with Members, comments are found below each post.
Epizyme was founded in 2007, and trying to create drugs to treat patient's cancer by focusing on genetically-linked differences between normal and cancer cells. Cancer areas of focus include leukemia, Non-Hodgkin's lymphoma and breast cancer. One of the Epizme cofounders, H. Robert Horvitz, won the Nobel Prize in Medicine in 2002 for "discoveries concerning genetic regulation of organ development and programmed cell death."
Before discussing the drug targets of Epizyme, understanding epigenetics is crucial to comprehend the company's goals.
Genetic components are the DNA sequences that are 'inherited.' Some of these genes are stronger than others in their expression (e.g., eye color). Yet, some genes turn on or off due to external factors (environmental), and it is und...
Note: The material presented in this commentary is provided for
informational purposes only and is based upon information that is
considered to be reliable. However, neither PSW Investments, LLC d/b/a PhilStockWorld (PSW)
nor its affiliates
warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither PSW nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance, including the tracking of virtual trades and portfolios for educational purposes, is not necessarily indicative of future results. Neither Phil, Optrader, or anyone related to PSW is a registered financial adviser and they may hold positions in the stocks mentioned, which may change at any time without notice. Do not buy or sell based on anything that is written here, the risk of loss in trading is great.
This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only intended at the moment of their issue as conditions quickly change. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.
Site owned and operated by PSW Investments, LLC. Contact us at: 403 Central Avenue, Hawthorne, NJ 07506. Phone: (201) 743-8009. Email: firstname.lastname@example.org.